Clinical trials: Human T-lymphotropic Virus 1
HAM/TSP
Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
Background: HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare, progressive disease. It occurs in some people infected with the HTLV-1 virus.
- Trial name
- NCT04799288
- Testing
- Teriflunomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-1-associated Myelopathy
Rituximab for HTLV-1-associated Myelopathy
Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.
- Trial name
- NCT04004819
- Testing
- Rituximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
HTLV-I Infections, HTLV-II Infections
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
- Conditions
- HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2
- Trial name
- NCT03226119
- Testing
- MP Diagnostics HTLV Blot 2.4
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- MP Biomedicals, LLC
HTLV-I
A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis
Doctors of the University of West Indies, the Caribbean Epidemiology Center (CAREC) and the National Cancer Institute have been studying the epidemiology of HTLV-I and its role in the etiology and pathogenesis of adult T-cell…
- Trial name
- NCT00340821
- Where
- Jamaica
- Volunteers
- 1,800 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Precancerous/Nonmalignant Condition
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1.
- Trial name
- NCT00854581
- Testing
- PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma.
- Conditions
- Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
- Trial name
- NCT02631746
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pharmacogenomic Study
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
HTLV-I Infection
Raltegravir for HAM/TSP
Background: Human T-cell lymphotropic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an infection of the spinal cord.
- Trial name
- NCT01867320
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Overactive Bladder Associated With HTLV-1
A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder
It's a double blind, placebo controlled study to assess the efficacy of Propantheline Bromide to treat overactive bladder (OAB) in HTLV 1 infected patients.
- Trial name
- NCT01640002
- Testing
- Propantheline Bromide
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
The purpose of this study is to determine the safety of the combination of CHOP plus daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.
- Trial name
- NCT01418430
- Testing
- CHOP-daclizumab
- Where
- United Kingdom
- Sponsor
- King's College Hospital NHS Trust
HTLV-1, Tropical Spastic Paraparesis
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
In this study the investigators are going to evaluate the efficacy pentoxifyline in HTLV-1 patients with neurological diseases: HAM/TSP or neurogenic bladder.
- Conditions
- HTLV-1, Tropical Spastic Paraparesis, Immune System Diseases, Physical Disability
- Trial name
- Pentox (NCT01472263)
- Testing
- Pentoxifylline
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Human T-Lymphotrophic Virus Type I and/or Type II
Evaluation of InnoLIA HTLV I/II Score
The InnoLIA HTLV I/II Score is an in vitro diagnostic test for confirmation of antibodies to human T-cell lymphotropic virus (HTLV) type I and type II in human blood samples.
- Trial name
- NCT01149837
- Testing
- InnoLIA HTLV I/II Score line immunoassay
- Where
- United States
- Volunteers
- 3,305 people, healthy volunteers welcome
- Sponsor
- Creative Testing Solutions
T Cell Leukemia, Adult, Leukemia, Adult T-Cell
Ruxolitinib for Adult T-Cell Leukemia
Background: The human T-cell leukemia virus 1 (HTLV-1) causes adult T-cell leukemia (ATL). Infection does not immediately cause ATL, but it can develop over time.
- Conditions
- T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated
- Trial name
- NCT01712659
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
HTLV-I Infections, Tropical Spastic Paraparesis
Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection
This is a pilot study of intervention in a group of patients with tropical spastic paraparesis/ myelopathy to evaluate virologic and clinical response of raltegravir plus zidovudine in this group of patients.
- Trial name
- NCT02655471
- Testing
- "Raltegravir" and "Zidovudine"
- Where
- Peru
- Volunteers
- 10 people
- Sponsor
- Universidad Peruana Cayetano Heredia
Human T-cell Leukemia Virus Type 1 Infection
Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load
This is a study of the effect of raltegravir on human T-cell leukemia virus type 1 (HTLV-1) viral load in asymptomatic patients. The study will enroll 14 subjects for a period of 2 months of treatment and 1 month of followup.
- Trial name
- NCT01620736
- Testing
- Raltegravir
- Sponsor
- Washington University School of Medicine
HAM
Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)
HTLV-1 Associated Myelopathy is a chronic disease of the spinal cord, caused by a virus called human T lymphotropic virus type 1（HTLV-1）.
- Trial name
- NCT02961712
- Testing
- NK cells, amniotic epithelial cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
HTLV-I-Associated Myelopathy
Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
An open-label, non-randomised, uncontrolled, proof-of-concept study of patients with HTLV-I-associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
- Trial name
- NCT01343355
- Testing
- Tamibarotene
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- St. Marianna University School of Medicine
Tropical Spastic Paraparesis, HTLV-1
Urological Physical Therapy in HTLV-1 With Urinary Symptoms
Urological physical therapy is described to improve urinary symptoms in patients with myelopathy or neurological dysfunction and to increase the quality of life.
- Trial name
- UROHTLV (NCT01651819)
- Testing
- Urological physical therapy
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
HTLV-I Infections, HTLV-II Infections
Evaluation of the MP Diagnostics HTLV Blot 2.4
The purpose of this study is: 1. To assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4. 2. To conduct a sensitivity analysis of the HTLV Blot 2.4 using a known positive population.
- Conditions
- HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2
- Trial name
- NCT01467024
- Testing
- CDPHL Algorithm
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- MP Biomedicals, LLC
HTLV-1 Associated Myelopathy
A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)
The objective of this study is to assess the efficacy and safety of KW-0761 after intravenous injections in subjects with HTLV-1 associated myelopathy (HAM) in Japan.
- Trial name
- NCT03191526
- Testing
- KW-0761 0.3 mg/kg IV
- Where
- 16 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate [Oncovin], cyclophosphamide, and doxorubicin…
- Conditions
- Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
- Trial name
- NCT04301076
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 19 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)